Appendix 3Y – Change of Director’s Interest Notice 2022 Announcements . Financial . Regulatory 07.11.2022
CLINUVEL Pharmaceuticals Investor Briefing Melbourne 2022 Announcements . Corporate . Presentation 21.10.2022
First vitiligo patient enrolled in afamelanotide monotherapy study 2022 Announcements . Clinical . Regulatory 20.10.2022
CLINUVEL PHARMACEUTICALS LTD Annual General Meeting – Notice of Meeting & Explanatory Memorandum 2022 2022 Announcements . Corporate . Regulatory 23.09.2022
H.C. Wainwright 24th Annual Global Investment Conference 2022 Announcements . Corporate . Presentation 13.09.2022
CLINUVEL submits SCENESSE® label expansion for adolescent EPP patients 2022 Announcements . Clinical . Regulatory 05.09.2022